Senate Health And Human Services Committee Advances “Arizona Stem Cell Therapy Act”
By Ethan Faverino |
On Wednesday, the Arizona Senate Health and Human Services Committee has advanced SB 1214, the “Arizona Stem Cell Therapy Act.”
The bill, sponsored by Senator Janae Shamp (R-LD29), builds on Arizona’s established status as a “Right to Try” state. SB 1214 introduces comprehensive medical standards and ethical guidelines for stem cell therapies and birth tissue therapies.
The legislation permits physicians to offer certain non-FDA-approved treatments within their scope of practice, provided they adhere to strict requirements on sourcing, transparency, informed consent, and quality control.
“When Arizona patients pursue innovative therapies, they deserve to know treatments are being delivered safely and responsibly,” stated Senator Shamp in a press relase announcing the advancement of the bill. “This legislation puts medical guardrails in place, strengthens transparency, and helps ensure bad actors cannot take advantage of vulnerable people searching for hope. We are promoting access to therapies while making sure patients know they are receiving care that meets recognized medical standards.”
Key provisions of SB 1214 include:
- An explicit prohibition on the use of cells or tissues derived from aborted fetuses or embryos in any stem cell or birth tissue therapy, with willful violations classified as a Class 5 felony and subject to professional discipline.
- Mandates that stem cells and birth tissues come from facilities registered with the FDA or accredited by recognized organizations, such as the American Association of Tissue Banks, the Association for the Advancement of Blood and Biotherapies, the National Marrow Donor Program, or the World Marrow Donor Association.
- Requirements for post-thaw viability reports for live stem cells, certificates of analysis for birth tissues (confirming negative tests for communicable diseases and presence of growth factors), and compliance with federal good manufacturing practices.
- Strong informed consent rules, requiring physicians to disclose that treatments are not FDA-approved, outline risks, benefits, alternatives, and encourage consultation with a primary care provider.
- Mandatory advertising disclosures in prominent type: “This notice is required by Arizona law. This physician offers one or more stem cell therapies or birth tissue therapies that are not approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy or birth tissue therapy.”
- Civil remedies allowing patients harmed by violations to seek $10,000 in statutory damages per violation, plus attorney fees.
Supporters, including medical experts who testified before the committee, stressed that the bill establishes a medical standard of care rather than a political one. They highlighted the clinical use of ethically sourced afterbirth tissues—such as placental or amniotic materials collected during planned C-sections from healthy mothers and deliveries—as a safe, effective approach for regenerative applications.
Healthcare policy expert Brigham Buhler emphasized the sourcing process: “The standard of care is to have a preplanned C-section so that you can get the most out of that tissue. So, healthy birth, healthy mother, pre-planned C-section is how they collect this discarded afterbirth tissue to avoid any cross contaminants. Those tissues, when applied appropriately into the right patient under the right standards of care, can be life changing. I’ve seen it impact soldiers who come back from war. I have seen it impact patients with Alzheimer’s, dementia. We’ve helped orthopedic injuries, knees, shoulders, elbows, soft tissue. The beauty of these products is they’re healing you from within.”
Dr. Pradeep Albert reinforced the medical rationale for excluding aborted tissue: “We don’t use aborted tissue, not from a political point of view, but from a medical point of view. Placenta tissue contains DNA from both the mother and the father, which helps regenerate soft tissue. There is no country on the planet that uses aborted tissue for regenerative stem cell therapies, like injections into joints, because it can cause tumors and other serious problems.”
The bill now advances to the Senate floor for further consideration.
Ethan Faverino is a reporter for AZ Free News. You can send him news tips using this link.
